Manjot K. Gill, MD, MS, Steven Ferrucci, OD, FAAO - Driving Diagnosis and Navigating the Role of Anti-VEGF Therapies in Managing Retinal Vein Occlusion
Please visit answersincme.com/SYV860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, two experts in retinal vein occlusion (RVO) discuss diagnosis and anti-VEGF treatment of the condition. Upon completion of this activity, participants should be better able to: Explain the rationale for exploring longer-acting anti-VEGF treatment for patients with RVO; Recognize the importance of early diagnosis to address the burden of RVO; and Propose optimized, patient-centered treatment plans for the multidisciplinary management of patients with RVO.
-------- Â
16:29
--------
16:29
Asim V. Farooq, MD, Erica L. Mayer, MD, MPH - Ocular Safety in Breast Cancer Care: What Eye Clinicians Need to Know About Novel Oral Endocrine Therapies
Please visit answersincme.com/XCG860 to participate, download slides and supporting materials, complete the post test, and obtain credit. This educational activity brings together leading experts in ophthalmology and oncology to explore clinical strategies for managing ocular adverse events associated with a novel class of therapies for advanced breast cancer: the oral selective estrogen receptor degraders (SERDs). Faculty will share key insights and practical guidance on identifying and managing common ocular side effects—particularly photopsia and dry eye—with the goal of enhancing patient care and improving quality of life for individuals navigating survivorship with advanced breast cancer. Upon completion of this activity, participants should be better able to: Recognize the implications of using oral SERDs in HR-positive, HER2-negative breast cancer for ophthalmic practice; Describe the ocular toxicities associated with oral SERDs used in breast cancer treatment; and Apply multidisciplinary strategies to facilitate the detection and management of ocular toxicities in patients receiving oral SERDs.
-------- Â
18:58
--------
18:58
Priya Vakharia, MD - The Long View in Neovascular Age-Related Macular Degeneration: Practical Insights on Long-Acting Anti-VEGF Treatment
Please visit answersincme.com/XWJ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, a retina expert discusses the role of long-acting anti–vascular endothelial growth factor (VEGF) therapy in neovascular age-related macular degeneration (nAMD). Upon completion of this activity, participants should be better able to: Recognize the rationale for long-acting anti-VEGF therapy in nAMD; Select the optimal long-acting anti-VEGF therapy for individual patients with nAMD; and Integrate practical strategies to enhance the clinical implementation of long-acting anti-VEGF therapy in patients with nAMD.
-------- Â
18:05
--------
18:05
David S. Boyer, MD / Irving Posalski, MD - PCP-Specialists Share a Lens to Magnify Outcomes With VEGF-Targeting Agents for DME
Please visit answersincme.com/GCB860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in the management of diabetic macular edema (DME) discuss the primary care physician (PCP) and ophthalmologist’s partnership in the care for patients with DME and optimizing treatment with VEGF-targeting agents. Upon completion of this activity, participants should be better able to: Explain how extending treatment intervals for DME can improve patient satisfaction and treatment persistence with intravitreal anti-VEGF therapy; Discuss the clinical benefits of longer-acting intravitreal anti-VEGF agents in the treatment of DME; Describe multidisciplinary care plans that improve the long-term treatment outcomes of patients with patients with DME; and Outline strategies for optimizing DME outcomes in the primary care setting. This activity is intended for US healthcare professionals only.
-------- Â
15:49
--------
15:49
Peter Lio, MD - AI in Healthcare: A Primer for the Practicing Clinician
Please visit answersincme.com/WZP860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert dermatologist—who is also an early adopter of generative artificial intelligence (AI)—discusses foundational elements of this emerging technology and its implications in healthcare, both for clinicians and patients. Upon completion of this activity, participants should be better able to: Describe how generative AI is impacting the practice of medicine both from the clinicians’ and patients’ perspectives; and Assess the potential benefits and risks of using generative AI in medical practice.
Get answers in 25 minutes or less from world-class experts and earn CME/CE credit with CME in Minutes: Education in Ophthalmology by Answers in CME. Benefit from digests of latest advancements, thoughtful case studies, and nuanced perspectives anytime, anywhere, and on any device. Inspiring and engaging programs designed for busy healthcare professionals to cover the diagnosis, treatment, follow-up, and clinical management of conditions in ophthalmology. Earning your CME/CE credit has never been faster or easier. Download the URL for each individual program to request continuing education credit or access the slides.
South Africa